Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis
PLOS One · 25.04.2025 · 20 (4) · e0320783
DOI: 10.1371/journal.pone.0320783 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS One, online erschienen am 25.04.2025. Verfasst von Di Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Tianjin Third Central Hospital, The Third Central Clinical College of Tianjin Medical University, Tianjin Key Laborato…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prognostic significance of KRAS and BRAF mutations is well-established in metastatic colorectal cancer (CRC) but remains uncertain in early-stage tumors. This study retrospectively analyzed 47 stage II/III CRC patients undergoing curative surgery to assess the association of mutations in KRAS , NRAS , BRAF , and PIK3CA with overall survival (OS) and disease-free survival (DFS). Additionally, a meta-analysis was conducted to validate the prognostic relevance of these gene mutations. We included post hoc analyses of phase III randomized controlled trials (RCTs) in stage II/III patients receiving adjuvant therapy after curative resection in the meta-analysis. Pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated using a random-effect model in the overall population, stratified subgroups adjusted for microsatellite instability (MSI) status, and within MSI-high (MSI-H) and microsatellite-stable (MSS) populations. In the retrospective cohort, mutations in KRAS , NRAS , BRAF , and PIK3CA were identified in 29.8%, 4.3%, 8.5%, and 14.9% of patients, respectively. No significant association between individual genes and survival was observed. However, in MSS patients, concurrent mutations were significantly associated with shorter OS and DFS (log-rank test, P < 0.05). The meta-analysis incorporated 13 eligible studies, including 15,034 patients. Pooled analyses revealed that KRAS and BRAF mutations were significantly linked to poor OS ( KRAS : HR = 1.25, 95%CI: 1.06-1.47, P = 0.008; BRAF : HR = 1.43, 95%CI: 1.26-1.63, P < 0.001) and DFS ( KRAS : HR = 1.36, 95%CI: 1.21-1.53, P < 0.001; BRAF : HR = 1.21, 95%CI: 1.02-1.44, P = 0.032). The prognostic impact of BRAF mutation increased with MSI adjustment compared those without MSI adjustment. In MSS tumors, KRAS -mutant patients demonstrated significantly shorter DFS (HR = 1.63, 95%CI: 1.25-2.13, P < 0.001), while BRAF -mutant patients exhibited reduced OS (HR = 1.53, 95%CI: 1.24-1.89, P < 0.001) and DFS (HR = 1.72, 95%CI: 1.20-2.46, P = 0.003) compared to wildtype patients. Conversely, no significant survival differences were found between mutant and wildtype patients in the MSI-H population. Although PIK3CA mutation was nominally associated with OS (HR = 0.86, 95%CI: 0.75-1.00, P = 0.046), the pooled result lacked robustness. In conclusion, KRAS and BRAF mutations had a negative prognostic impact on MSS stage II/III CRC patients receiving adjuvant therapy following curative resection. These patients may benefit from more effective adjuvant treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Tianjin Third Central Hospital, The Third Central Clinical College of Tianjin Medical University, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Ce…
ORCID-Profile: Zili Zhang
Zitieren
APA
Kang, D., Li, J., Li, Y., Xu, J., Yang, J., & Zhang, Z. (2025). Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis. PLOS One, 20(4), e0320783. https://doi.org/10.1371/journal.pone.0320783
Vancouver
Kang D, Li J, Li Y, Xu J, Yang J, Zhang Z. Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis. PLOS One. 2025;20(4):e0320783. doi:10.1371/journal.pone.0320783
BibTeX
@article{Kang2025,
author = {Kang, Di and Li, Jing and Li, Yangyang and Xu, Jingquan and Yang, Jianlei and Zhang, Zili},
title = {Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {4},
pages = {e0320783},
doi = {10.1371/journal.pone.0320783}
}
EUVIMED